Anesthesiology, Pain Research / 29.10.2024
Suzetrigine: First New Class of Acute Pain Medicine Data Presented at ASA 2024 Meeting
MedicalResearch.com Interview with a Vertex spokesperson.
MedicalResearch.com: What is the background for this study? What are the main findings?
- We presented Phase 3 data for our investigational, oral pain signal inhibitor, suzetrigine, at ANESTHESIOLOGY 2024, the American Society of Anesthesiologists’ annual meeting. The Phase 3 data were previously announced in January 2024, and this is the first time the findings were presented to the medical community. The data were featured in the “Best Abstracts” session at the meeting.
- Our Phase 3 acute pivotal program for suzetrigine included two randomized, double-blind, placebo-controlled, pivotal trials, one following abdominoplasty surgery and one following bunionectomy surgery, as well as a single arm safety and effectiveness study which enrolled patients with a broad range of surgical and non-surgical pain conditions. All three studies demonstrated compelling and consistent efficacy and safety across multiple acute pain conditions and settings.
- Together, the data demonstrate suzetrigine’s potential to offer a safe, well tolerated and effective alternative to the current acute pain treatment paradigm, without addictive potential.